Immunotherapy has fundamentally transformed the therapeutic landscape of lung adenocarcinoma, particularly through ICIs such as PD‐1 and PD‐L1 blockers that disrupt tumor immune evasion mechanisms [10, 42, 43]. The gene discussed is CD274; the disease is lung adenocarcinoma.